CARDIO INNOVATIVE SYSTEMS : revenue, balance sheet and financial ratios

CARDIO INNOVATIVE SYSTEMS is a French company founded 16 years ago, specialized in the sector Ingénierie, études techniques. Based in LOUVIERS (27400), this company of category PME shows in 2022 a revenue of 5 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - CARDIO INNOVATIVE SYSTEMS (SIREN 513953711)
Indicator 2022 2020 2019 2018 2017 2016
Revenue 5 074 € 2 153 € 2 045 € 4 758 € 18 148 € N/C
Net income 9 184 € 93 920 € -280 508 € -105 115 € -180 127 € -197 278 €
EBITDA -50 722 € -62 584 € -90 907 € -199 325 € -329 560 € -450 276 €
Net margin 181.0% 4362.3% -13716.8% -2209.2% -992.5% N/C

Revenue and income statement

Im Jahr 2022 erzielt CARDIO INNOVATIVE SYSTEMS einen Umsatz von 5 k€. Der Umsatz geht im Zeitraum 2017-2022 zurück (CAGR: -22.5%). Vs 2020, Wachstum von +136% (2 k€ -> 5 k€). Nach Abzug des Verbrauchs (0 €) beträgt die Bruttomarge 5 k€, d.h. eine Rate von 100%. Dieses Verhältnis misst die Fähigkeit, aus der Geschäftstätigkeit Wert zu schaffen. EBITDA (= Bruttomarge - Personalkosten - Steuern) erreicht -51 k€, was -999.6% des Umsatzes entspricht. Positiver Schereneffekt: EBITDA-Marge verbessert sich um +1907.2 Punkte. Negatives EBITDA bedeutet, dass der Betrieb die laufenden Kosten nicht deckt. Das Nettoergebnis beträgt 9 k€, d.h. 181.0% des Umsatzes.

Revenue (2022) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

5 074 €

Gross margin (2022) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

5 074 €

EBITDA (2022) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-50 722 €

EBIT (2022) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-2 092 €

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

9 184 €

EBITDA margin (2022) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-999.6%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

Die Verschuldungsquote (= Finanzschulden / Eigenkapital x 100) beträgt 467%. Kritische Situation: Die Schulden übersteigen das Eigenkapital erheblich. Die finanzielle Autonomie (= Eigenkapital / Bilanzsumme x 100) erreicht 10%. Geringe Autonomie: Das Unternehmen ist stark von externer Finanzierung abhängig.

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

467.395%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

10.067%

Cash flow / Revenue (2022) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-4834.608%

Repayment capacity (2022) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-0.918

Solvency indicators evolution
CARDIO INNOVATIVE SYSTEMS

Sector positioning

Verschuldungsgrad
467.39 2022
2019
2020
2022
Q1: 0.0
Med: 10.4
Q3: 59.95
Average

Im Jahr 2022 liegt über dem Median der Branche das verschuldungsgrad von CARDIO INNOVATIVE SYSTEMS (467.39). Dieses Verhältnis misst das Gewicht der Schulden im Verhältnis zum Eigenkapital. Eine Reduzierung könnte die finanzielle Stärke verbessern.

Finanzielle Autonomie
10.07% 2022
2019
2020
2022
Q1: 10.97%
Med: 36.06%
Q3: 59.83%
Average -11 pts over 3 years

Im Jahr 2022 liegt unter dem Median der Branche das finanzielle autonomie von CARDIO INNOVATIVE SYSTEMS (10.1%). Dieses Verhältnis stellt den Anteil des Eigenkapitals an der Gesamtfinanzierung dar. Eine Verbesserung würde die Wettbewerbsposition stärken.

Rückzahlungsfähigkeit
-0.92 ans 2022
2019
2020
2022
Q1: 0.0 ans
Med: 0.01 ans
Q3: 1.24 ans
Ausgezeichnet -50 pts over 3 years

Im Jahr 2022 liegt in den unteren 25% der Branche, was positiv ist das rückzahlungsfähigkeit von CARDIO INNOVATIVE SYSTEMS (-0.9 an). Dieses Verhältnis gibt die Anzahl der Jahre an, die zur Rückzahlung der Schulden mit dem Cashflow benötigt werden. Eine kurze Kapazität spiegelt kontrollierte Schulden und gute Cashflow-Generierung wider.

Liquidity ratios

Die Liquiditätsquote beträgt 491.59. Das Unternehmen verfügt über 2€ liquide Mittel für jeden 1€ kurzfristiger Schulden.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

491.594

Interest coverage (2022) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.0

Liquidity indicators evolution
CARDIO INNOVATIVE SYSTEMS

Sector positioning

Liquiditätsquote
491.59 2022
2019
2020
2022
Q1: 148.19
Med: 225.94
Q3: 385.62
Ausgezeichnet

Im Jahr 2022 liegt in den oberen 25% der Branche das liquiditätsquote von CARDIO INNOVATIVE SYSTEMS (491.59). Dieses Verhältnis misst die Fähigkeit, kurzfristige Schulden mit Umlaufvermögen zu decken. Ein Verhältnis über 1 gewährleistet komfortable Deckung kurzfristiger Fälligkeiten.

Zinsdeckung
0.0x 2022
2019
2020
2022
Q1: 0.0x
Med: 0.0x
Q3: 1.46x
Average

Im Jahr 2022 liegt unter dem Median der Branche das zinsdeckung von CARDIO INNOVATIVE SYSTEMS (0.0x). Dieses Verhältnis gibt an, wie oft das Betriebsergebnis die Zinsaufwendungen deckt. Eine Verbesserung würde die Wettbewerbsposition stärken.

Working capital requirement (WCR) and payment terms

Der Betriebskapitalbedarf (WCR) misst die zeitliche Lücke. Durchschnittliche Kundenzahlungsfrist: 31249 Tage. Lieferantenfrist: 50 Tage. Die Lücke von 31199 Tagen belastet den Cashflow. Der WCR repräsentiert 27325 Tage Umsatz.

Operating WCR (2022) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

385 137 €

Customer credit (2022) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

31249 j

Supplier credit (2022) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

50 j

Inventory turnover (2022) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2022) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

27325 j

WCR and payment terms evolution
CARDIO INNOVATIVE SYSTEMS

Positioning of CARDIO INNOVATIVE SYSTEMS in its sector

Comparison with sector Ingénierie, études techniques

Valuation estimate

Based on 63 transactions of similar company sales in 2022, the value of CARDIO INNOVATIVE SYSTEMS is estimated at 2 658 € (range 1 278€ - 6 751€). The price/revenue ratio is 0.16x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2022
63 tx
1k€ 2k€ 6k€
2 658 € Range: 1 278€ - 6 751€
NAF 5 année 2022

Valuation detail by method

Ajustez les pondérations selon votre analyse

Revenue Multiple 30%
5 074 € × 0.16x
Estimation 831 €
406€ - 1 448€
Net Income Multiple 20%
9 184 € × 0.6x
Estimation 5 399 €
2 586€ - 14 706€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 63 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Ingénierie, études techniques)

Compare CARDIO INNOVATIVE SYSTEMS with other companies in the same sector:

Voir toutes les statistiques du secteur Ingénierie, études techniques

Frequently asked questions about CARDIO INNOVATIVE SYSTEMS

What is the revenue of CARDIO INNOVATIVE SYSTEMS ?

The revenue of CARDIO INNOVATIVE SYSTEMS in 2022 is 5 k€.

Is CARDIO INNOVATIVE SYSTEMS profitable?

Yes, CARDIO INNOVATIVE SYSTEMS generated a net profit of 9 k€ in 2022.

Where is the headquarters of CARDIO INNOVATIVE SYSTEMS ?

The headquarters of CARDIO INNOVATIVE SYSTEMS is located in LOUVIERS (27400), in the department Eure.

Where to find the tax return of CARDIO INNOVATIVE SYSTEMS ?

The tax return of CARDIO INNOVATIVE SYSTEMS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does CARDIO INNOVATIVE SYSTEMS operate?

CARDIO INNOVATIVE SYSTEMS operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.